Cargando…
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis
Autores principales: | Au, Wing-Yan, Fong, Bonnie M., Tam, Sidney, Kwong, Yok-Lam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567333/ https://www.ncbi.nlm.nih.gov/pubmed/23053177 http://dx.doi.org/10.1007/s00277-012-1576-1 |
Ejemplares similares
-
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
por: Chin, Lynn, et al.
Publicado: (2022) -
Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond
por: Kumana, Cyrus R., et al.
Publicado: (2022) -
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015) -
Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
por: Tinajero, Jose, et al.
Publicado: (2022) -
Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside
por: Kumana, Cyrus R., et al.
Publicado: (2020)